Visus Therapeutics Presents Topline Clinical Data from Phase 3 Pivotal BRIO-I Trial of BRIMOCHOL™ PF for the Treatment of Presbyopia at Eyecelerator @ ASCRS 2023
Visus Therapeutics™ is a clinical-stage pharmaceutical company lighting the way to dramatically improve patient lives through the development of differentiated, best-in-class ophthalmic therapies.
And we're just getting started...DISCOVER OUR PIPELINE TODAY
With officies in Seattle and Orange County, Visus is home to our lead clinical candidate, BRIMOCHOL™ (carbachol + brimonidine tartrate), an eye drop being evaluated to correct the loss of near vision associated with presbyopia.
Visus Therapeutics announce spositive Phase 2 Topline results for Investigational Brimichol [& Brimochol F] for the treatment of presbropia